Merck Sees Options For Molnupiravir Past Pandemic

The antiviral for COVID-19 added $952m to Merck's top line in 2021 and is forecast to deliver $5bn-$6bn in 2022, but CEO Davis sees potential for the product beyond the current pandemic, including potential combinations.